| Feature Type | Standardized | Nominal ANOVA | ||||
|---|---|---|---|---|---|---|
| mRNA | Gefitinib | GDSC1000 | pan-cancer | AAC | 0.072 | 0.05 |
| mRNA | tipifarnib | CTRPv2 | pan-cancer | AAC | 0.068 | 0.05 |
| mRNA | GDC-0941 | gCSI | pan-cancer | AAC | 0.12 | 0.05 |
| mRNA | HBX-41108 | CTRPv2 | pan-cancer | AAC | -0.094 | 0.05 |
| mRNA | 1S,3R-RSL-3 | CTRPv2 | pan-cancer | AAC | -0.072 | 0.05 |
| mRNA | AZD-2281 | FIMM | pan-cancer | AAC | 0.32 | 0.05 |
| mRNA | Bortezomib | FIMM | pan-cancer | AAC | 0.29 | 0.05 |
| mRNA | FK866 | GDSC1000 | pan-cancer | AAC | -0.064 | 0.06 |
| mRNA | CEP-701 | GDSC1000 | pan-cancer | AAC | -0.069 | 0.06 |
| mRNA | erlotinib:PLX-4032 (2:1 mol/mol) | CTRPv2 | pan-cancer | AAC | 0.079 | 0.06 |